



Unifying the care experience

APPENDIX 4E
PRELIMINARY FINAL
REPORT
YEAR ENDED
31 DECEMBER 2023

For personal use only



Appendix 4E

Preliminary Final Report Oneview Healthcare PLC ABN 610 611 768

1. Company Details

Name of Entity

Oneview Healthcare PLC

ABN or equivalent
company reference

610 611 768

Financial year ended
(current period)

31 December 2023

Financial year ended
(previous period)

31 December 2022

2. Results for announcement to the market

| | Up/down | % change | 31 December 2023 €'000 | 31 December 2022 €'000 |
|---------------------------------------------------------------------------------------------------|---------|-------------|------------------------------------------|------------------------------------------|
| Recurring revenue from ordinary activities | Up | 7% | 6,600 | 6,185 |
| Total revenue from ordinary activities | Up | 5% | 9,397 | 8,921 |
| (Loss) from ordinary activities after tax attributable to members (including significant items) | Down | 18% | (8,935) | (10,869) |
| (Loss) from ordinary activities after tax attributable to members (excluding significant items *) | Down | 20% | (6,252) | (7,815) |

* Significant items incurred include FX and non-cash share based payments.

3. Net Tangible Assets Per Security

| | 31 December 2023 € | 31 December 2022 € |
|----------------------------------|----------------------------------|----------------------------------|
| Net Tangible Assets Per Security | 0.013 | 0.004 |

Net tangible assets are defined as the net assets of Oneview Healthcare PLC less intangible assets. A small proportion of the Company's assets are intangible in nature. These assets are excluded from the calculation of net tangible assets per security shown above.

4. Commentary on Results

The principal activity of the Group is the development and sale of software for the healthcare sector and the provision of related consultancy services.

The directors report that revenue for the year from continuing operations amounted to €9,397,373 (2022: €8,921,499), an increase of 5%. Recurring revenue for the year amounted to €6,600,035 (2022: €6,185,160), an increase of 7% and continues to grow as the company deploys across its customer base.

As at 31 December 2023, the Oneview solution was live in 10,151 beds with a further 5,670 beds contracted but not yet installed.

5. Dividends

The Company has not declared, and does not propose to pay, any dividends for the year ended 31 December 2023 (31 December 2022: Nil). There are no dividend or dividend reinvestment plans in operation.

6. Details of entities over which control has been gained or lost during the period

There are no entities over which control has been gained or lost in the period.

7. Associates and joint venture entities

There are no associate or joint venture entities.

8. Audit status

This Appendix 4E and the included financial information are based on financial statements which have not been audited, but are in the process of being audited.

9. Foreign entity accounting standards

The Financial Statements contained within the Preliminary Final Report are measured and recognised in accordance with International Financial Reporting Standards, as adopted by the European Union.

10. Financial Report

The following financial report included in this Appendix 4E does not include all notes of the type normally included within the annual financial report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and operating, financial and investing activities of the consolidated entity as the full annual financial report. This financial report should be read in conjunction with any public announcements made by Oneview Healthcare PLC in accordance with the continuous disclosure obligations of the ASX Listing Rules.

The accounting policies are the same as those applied in the most recent interim financial report and the previous annual report.

Consolidated Statement of Total Comprehensive Income

for the year ended 31 December 2023

| | | 2023 Unaudited | 2022 Audited |
|--------------------------------------------------------------------------------|------|--------------------|-----------------|
| | Note | € | € |
| Revenue - continuing operations | 2 | 9,397,373 | 8,921,499 |
| Cost of sales | | (3,232,587) | (3,575,857) |
| Gross profit | | 6,164,786 | 5,345,642 |
| Other income | 3 | - | 1,360,637 |
| Sales and marketing expenses | | (3,127,283) | (3,918,579) |
| Product development and delivery expenses | | (8,341,433) | (10,070,026) |
| General and administrative expenses | | (3,069,122) | (3,543,075) |
| Operating loss | | (8,373,052) | (10,825,401) |
| Finance charges | | (517,038) | (162,459) |
| Finance income | | 5,254 | 63,180 |
| Loss before tax | | (8,884,836) | (10,924,680) |
| Income tax | | (49,735) | 55,221 |
| Loss for the year | | (8,934,571) | (10,869,459) |
| Attributable to ordinary shareholders | | (8,934,571) | (10,869,459) |
| <i>Loss per share</i> | | | |
| Basic | 4 | (0.02) | (0.02) |
| Diluted | 4 | (0.02) | (0.02) |
| Other comprehensive gain/(loss) | | | |
| <i>Items that will or may be reclassified to profit or loss:</i> | | | |
| Foreign currency translation differences on foreign operations (no tax impact) | | 158,081 | (80,260) |
| Other comprehensive loss, net of tax | | 158,081 | (80,260) |
| Total comprehensive loss for the year | | (8,776,490) | (10,949,719) |

The total comprehensive loss for the year is entirely attributable to equity holders of the Group.

Consolidated Statement of Financial Position

as at 31 December 2023

| | | 2023 Unaudited | 2022 Audited |
|--------------------------------------|------|-------------------|-----------------|
| | Note | € | € |
| Non-current assets | | | |
| Intangible assets | 5 | 491,386 | 264,877 |
| Property, plant and equipment | 6 | 1,037,034 | 613,779 |
| Research and development tax credit | 7 | 461,061 | 639,639 |
| Total non-current assets | | 1,989,481 | 1,518,295 |
| Current assets | | | |
| Inventories | | 2,240,906 | 1,227,691 |
| Trade and other receivables | 7 | 5,708,046 | 3,342,163 |
| Contract assets | | 430,906 | 240,035 |
| Current income tax receivable | | - | 16,025 |
| Cash and cash equivalents | | 11,548,825 | 6,409,936 |
| Total current assets | | 19,928,683 | 11,235,850 |
| Total assets | | 21,918,164 | 12,754,145 |
| Equity | | | |
| Issued share capital | 10 | 671,482 | 534,990 |
| Share premium | 10 | 134,082,384 | 120,369,325 |
| Treasury reserve | | (2,586) | (2,586) |
| Other undenominated capital | | 4,200 | 4,200 |
| Translation reserve | | 172,075 | 13,994 |
| Reorganisation reserve | | (1,351,842) | (1,351,842) |
| Share based payments reserve | | 7,217,895 | 6,446,943 |
| Retained earnings | | (131,653,947) | (123,758,477) |
| Total equity | | 9,139,661 | 2,256,547 |
| Non-current liabilities | | | |
| Trade and other payables | 9 | 247,225 | 2,789,637 |
| Lease liabilities | | 782,456 | 370,732 |
| Deferred income | | 12,058 | 20,295 |
| Total non-current liabilities | | 1,041,739 | 3,180,664 |
| Current liabilities | | | |
| Trade and other payables | 8 | 11,570,211 | 7,144,655 |
| Lease liabilities | | 152,866 | 172,279 |
| Current income tax liabilities | | 13,687 | - |
| Total current liabilities | | 11,736,764 | 7,316,934 |
| Total liabilities | | 12,778,503 | 10,497,598 |
| Total equity and liabilities | | 21,918,164 | 12,754,145 |

Consolidated Statement of Cash Flows

for the year ended 31 December 2023

| | | 2023 Unaudited | 2022 Audited |
|------------------------------------------------------------|------|--------------------|--------------------|
| | Note | € | € |
| Cash flows from operating activities | | | |
| Receipts from customers | | 9,721,389 | 8,838,970 |
| Legal claim settlement proceeds | | - | 1,360,637 |
| Payments to employees and suppliers | | (16,812,803) | (19,609,240) |
| Finance charges paid | | (127,455) | (104,932) |
| Interest received | | 5,254 | 570 |
| Research and development tax credit received | | - | 621,561 |
| Income tax paid | | (50,173) | (17,647) |
| Net cash used in operating activities | 11 | (7,263,788) | (8,910,081) |
| Cash flows from investing activities | | | |
| Purchase of property, plant and equipment | 6 | (118,444) | (44,518) |
| Acquisition of intangible assets | 5 | (402,933) | - |
| Net cash used in investing activities | | (521,377) | (44,518) |
| Cash flows from financing activities | | | |
| Proceeds from issue of shares | | 13,839,783 | 309,458 |
| Transaction costs | | (548,527) | (91,640) |
| Repayment of lease liabilities | | (253,778) | (317,925) |
| Net cash provided by/(used in) financing activities | | 13,037,478 | (100,107) |
| Net increase/(decrease) in cash held | | 5,252,313 | (9,054,706) |
| Foreign exchange impact on cash and cash equivalents | | (113,424) | 288,657 |
| Cash and cash equivalents at beginning of financial year | | 6,409,936 | 15,175,985 |
| Cash and cash equivalents at end of financial year | | 11,548,825 | 6,409,936 |

Consolidated Statement of Changes in Equity

as at 31 December 2023

| | Share capital | Share premium | Treasury reserve | Other undenominated capital | Reorganisation reserve | Share based payments reserve | Translation reserve | Retained earnings | Total equity |
|----------------------------------------------------------------------------------|----------------|--------------------|------------------|-----------------------------|------------------------|------------------------------|---------------------|----------------------|---------------------|
| | € | € | € | € | € | € | € | € | € |
| As at 1 January 2022 | 518,477 | 120,071,867 | (2,586) | 4,200 | (1,351,842) | 4,344,439 | 94,254 | (113,778,692) | 9,900,117 |
| Loss for the year | - | - | - | - | - | - | - | (10,869,459) | (10,869,459) |
| Foreign currency translation | - | - | - | - | - | - | (80,260) | - | (80,260) |
| Total comprehensive loss | - | - | - | - | - | - | (80,260) | (10,869,459) | (10,949,719) |
| <i>Transactions with shareholders</i> | | | | | | | | | |
| Exercise of share options | 12,000 | 297,458 | - | - | - | (68,758) | - | 68,758 | 309,458 |
| Share based compensation to employees | - | - | - | - | - | 2,996,691 | - | - | 2,996,691 |
| Vesting of restricted share unit awards | 4,513 | - | - | - | - | (609,773) | - | 605,260 | - |
| Transfer to retained earnings in respect of expired restricted share unit awards | - | - | - | - | - | (215,135) | - | 215,135 | - |
| Transfer to retained earnings in respect of expired options | - | - | - | - | - | (521) | - | 521 | - |
| As at 31 December 2022 | 534,990 | 120,369,325 | (2,586) | 4,200 | (1,351,842) | 6,446,943 | 13,994 | (123,758,477) | 2,256,547 |

Consolidated Statement of Changes in Equity (continued)

as at 31 December 2022

| | Share capital | Share premium | Treasury reserve | Other undenominated capital | Reorganisation reserve | Share based payments reserve | Translation reserve | Retained earnings | Total equity |
|----------------------------------------------------------------------------------|----------------|--------------------|------------------|-----------------------------|------------------------|------------------------------|---------------------|----------------------|--------------------|
| | € | € | € | € | € | € | € | € | € |
| As at 1 January 2023 | 534,990 | 120,369,325 | (2,586) | 4,200 | (1,351,842) | 6,446,943 | 13,994 | (123,758,477) | 2,256,547 |
| Loss for the year | - | - | - | - | - | - | - | (8,934,571) | (8,934,571) |
| Foreign currency translation | - | - | - | - | - | - | 158,081 | - | 158,081 |
| Total comprehensive loss | - | - | - | - | - | - | 158,081 | (8,934,571) | (8,776,490) |
| <i>Transactions with shareholders</i> | | | | | | | | | |
| Issue of ordinary shares | 126,724 | 13,713,059 | - | - | - | - | - | (548,527) | 13,291,256 |
| Issue of ordinary shares as consideration for services | 2,083 | - | - | - | - | (224,027) | - | 221,944 | - |
| Share based compensation to employees | - | - | - | - | - | 2,038,852 | - | - | 2,038,852 |
| Share based compensation to non-employees | - | - | - | - | - | 329,496 | - | - | 329,496 |
| Vesting of restricted share unit awards | 7,685 | - | - | - | - | (1,072,874) | - | 1,065,189 | - |
| Transfer to retained earnings in respect of expired restricted share unit awards | - | - | - | - | - | (299,740) | - | 299,740 | - |
| Transfer to retained earnings in respect of expired options | - | - | - | - | - | (755) | - | 755 | - |
| As at 31 December 2023 | 671,482 | 134,082,384 | (2,586) | 4,200 | (1,351,842) | 7,217,895 | 172,075 | (131,653,947) | 9,139,661 |

1. Statement of Significant Accounting Policies

Statement of compliance

This report is not a set of statutory financial statements and does not include all the information required for a complete set of financial statements, prepared in accordance with IFRS as adopted by the European Union. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since 31 December 2022. They should be read in conjunction with the statutory consolidated financial statements of the Group, which were prepared in accordance with IFRS as adopted by the European Union, as at and for the year ended 31 December 2022 and also in conjunction with any public announcements made by Oneview Healthcare PLC during the year.

Going Concern

The Group's financial statements have been prepared and presented on a going concern basis.

This report adopts the going concern basis of accounting, which contemplates the realisation of assets and the discharge of liabilities and commitments in the ordinary course of business.

During the year, the Company successfully conducted a Placement and Securities Purchase Plan (SPP) which raised A\$22.8 million (€13.8 million) before costs. The Company has an extensive sales pipeline, of which several opportunities are expected to be contracted in the coming months. Accordingly, the Directors believe the business has adequate levels of working capital to fund the Group's strategic goals. They believe, therefore, that the Group continues to be a going concern and that it will be able to pay its debts as and when they fall due, for a period of at least 12 months from the date of this report.

On this basis, the Directors believe that the going concern basis of presentation is appropriate. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Group not have the ability to continue as a going concern. If for any reason the Group is unable to continue as a going concern, it would impact on the Group's ability to realise assets at their recognised values and to extinguish liabilities in the normal course of business at the amounts stated in the consolidated financial statements.

Use of estimates and judgments

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected. In preparing this financial report, the significant judgments made by management in applying the Group's accounting policies and the key sources of estimation and uncertainty were the same as those that apply to the consolidated financial statements for the year ended 31 December 2022.

Notes to the Preliminary Final Report

for the year ended 31 December 2023

2. Revenue

Revenue by type

Recurring revenue:

| | 2023 Unaudited € | 2022 Audited € |
|----------------------------|------------------------|----------------------|
| Software usage and content | 4,261,096 | 3,978,661 |
| Support income | 2,194,692 | 2,055,044 |
| Licence fee | 144,247 | 151,455 |
| | 6,600,035 | 6,185,160 |

Non-recurring revenue:

| | | |
|-----------------|------------------|------------------|
| Hardware | 1,966,050 | 1,701,684 |
| Services income | 831,288 | 1,034,655 |
| | 2,797,338 | 2,736,339 |

Total revenue

| | |
|------------------|------------------|
| 9,397,373 | 8,921,499 |
|------------------|------------------|

Revenue attributable to geographic region:

| | 2023 Unaudited € | 2022 Audited € |
|------------------------------|------------------------|----------------------|
| Ireland | 42,684 | 4,200 |
| United States | 6,375,059 | 5,679,550 |
| Australia | 2,366,402 | 2,864,910 |
| Asia | 545,327 | 279,128 |
| Middle East and North Africa | 67,901 | 93,711 |

Total revenue

| | |
|------------------|------------------|
| 9,397,373 | 8,921,499 |
|------------------|------------------|

3. Other income

There was no other income in 2023. The other income in the prior year related to a commercial settlement agreed with aged care operator Regis Aged Care Pty Ltd in relation to the claim launched by the Company for breach of the Collaboration Agreement between the parties without admission of liability of either party. A settlement of A\$2 million (€1.36 million) was agreed and was received by the Company in May 2022. Legal fees of €0.07 million associated with the claim were incurred and paid during the prior year and are reflected in professional and legal fees within general and administrative costs.

4. Earnings per share

| | 2023 Unaudited € | 2022 Audited € |
|---------------------------------------------------------------|------------------------|----------------------|
| Basic earnings per share | | |
| Loss attributable to ordinary shareholders | (8,934,571) | (10,869,459) |
| Weighted average number of ordinary shares outstanding (i) | 588,668,829 | 522,319,679 |
| Basic loss per share | (0.02) | (0.02) |
| | | |
| | 2023 No. | 2022 No. |
| (i) Weighted-average number of ordinary shares (basic) | | |
| Issued ordinary shares at 1 January | 534,990,444 | 518,477,053 |
| Effect of shares issued | 53,678,385 | 3,842,626 |
| Weighted average number of ordinary shares at 31 December | 588,668,829 | 522,319,679 |

Basic loss per share is calculated by dividing the loss for the year after taxation attributable to ordinary shareholders by the weighted average number of ordinary shares in issue during the year.

| | 2023 Unaudited € | 2022 Audited € |
|------------------------------------------------------------|------------------------|----------------------|
| Diluted earnings per share | | |
| Loss attributable to ordinary shareholders | (8,934,571) | (10,869,459) |
| Weighted average number of ordinary shares outstanding (i) | 588,668,829 | 522,319,679 |
| Diluted loss per share | (0.02) | (0.02) |

4. Earnings per share (continued)

| | 2023 No. | 2022 No. |
|------------------------------------------------------------------|---------------------|---------------------|
| (ii) Weighted-average number of ordinary shares (diluted) | | |
| Issued ordinary shares at 1 January | 534,990,444 | 518,477,053 |
| Effect of shares issued | 53,678,385 | 3,842,626 |
| Weighted average number of ordinary shares at 31 December | 588,668,829 | 522,319,679 |

The calculation of diluted earnings per share has been based on the loss attributable to ordinary shareholders and weighted average number of ordinary shares outstanding after adjustments for the effects of all dilutive ordinary shares. Potential ordinary shares are treated as dilutive when, and only when, their conversion to ordinary shares would decrease EPS or increase the loss per share from continuing operations. As the Group is loss making there is no difference between the basic and diluted earnings per share. The number of ordinary shares, including potentially dilutive shares is 703,658,850 (2022: 567,057,257). The weighted average number of ordinary shares, including potentially dilutive shares, is 640,806,485 (2022: 562,689,187).

Notes to the Preliminary Final Report
for the year ended 31 December 2023

5. Intangible assets

| | Software € | Development costs € | Total € |
|-----------------------------------------------------------|----------------|---------------------------|------------------|
| Cost | | | |
| At 1 January 2022 | 215,685 | 5,213,747 | 5,429,432 |
| Foreign exchange translation differences | 5,602 | - | 5,602 |
| At 31 December 2022 | 221,287 | 5,213,747 | 5,435,034 |
| At 1 January 2023 | 221,287 | 5,213,747 | 5,435,034 |
| Additions | 18,006 | 384,927 | 402,933 |
| At 31 December 2023 | 239,293 | 5,598,674 | 5,837,967 |
| Accumulated amortisation and impairment losses | | | |
| At 1 January 2022 | 215,685 | 4,734,980 | 4,950,665 |
| Amortisation | - | 213,890 | 213,890 |
| Foreign exchange translation differences | 5,602 | - | 5,602 |
| At 31 December 2022 | 221,287 | 4,948,870 | 5,170,157 |
| At 1 January 2023 | 221,287 | 4,948,870 | 5,170,157 |
| Amortisation | - | 176,424 | 176,424 |
| At 31 December 2023 | 221,287 | 5,125,294 | 5,346,581 |
| Carrying amount | | | |
| At 1 January 2022 | - | 478,767 | 478,767 |
| At 31 December 2022 | - | 264,877 | 264,877 |
| At 31 December 2023 | 18,006 | 473,380 | 491,386 |

Notes to the Preliminary Final Report
for the year ended 31 December 2023

6. Property, plant and equipment

| | Fixtures, fittings and equipment € | Land and Buildings * € | Total € |
|------------------------------------------|-------------------------------------------------------|---------------------------------------|--------------------|
| Cost | | | |
| At 1 January 2022 | 1,507,336 | 2,002,916 | 3,510,252 |
| Additions during the year | 44,518 | - | 44,518 |
| Modification | - | (281,152) | (281,152) |
| Disposals | (15,794) | - | (15,794) |
| Foreign exchange translation differences | 22,772 | 47,190 | 69,962 |
| At 31 December 2022 | 1,558,832 | 1,768,954 | 3,327,786 |
| At 1 January 2023 | 1,558,832 | 1,768,954 | 3,327,786 |
| Additions during the year | 118,444 | 646,089 | 764,533 |
| Foreign exchange translation differences | (10,478) | (19,668) | (30,146) |
| At 31 December 2023 | 1,666,798 | 2,395,375 | 4,062,173 |
| Depreciation | | | |
| At 1 January 2022 | 1,283,667 | 943,700 | 2,227,367 |
| Charge for the year | 92,545 | 367,468 | 460,013 |
| Disposals | (9,827) | - | (9,827) |
| Foreign exchange translation differences | 16,568 | 19,886 | 36,454 |
| At 31 December 2022 | 1,382,953 | 1,331,054 | 2,714,007 |
| At 1 January 2023 | 1,382,953 | 1,331,054 | 2,714,007 |
| Charge for the year | 63,961 | 245,593 | 309,554 |
| Foreign exchange translation differences | 6,828 | (5,250) | 1,579 |
| At 31 December 2023 | 1,453,742 | 1,571,397 | 3,025,139 |
| Net book value | | | |
| At 1 January 2022 | 223,669 | 1,059,216 | 1,282,885 |
| At 31 December 2022 | 175,879 | 437,900 | 613,779 |
| At 31 December 2023 | 213,056 | 823,978 | 1,037,034 |

* Land and Buildings is comprised of Right of Use assets, held under leases.

7. Trade and other receivables

| | 2023 Unaudited € | 2022 Audited € |
|------------------------------------------------------|------------------------|----------------------|
| <i>Amounts falling due within one year:</i> | | |
| Trade receivables | 2,524,369 | 995,595 |
| Prepaid expenses and other current assets | 1,723,146 | 1,638,690 |
| Research and development tax credit | 1,460,531 | 628,224 |
| Sales tax recoverable | - | 79,654 |
| | 5,708,046 | 3,342,163 |
| <i>Amounts falling due after more than one year:</i> | | |
| Research and development tax credit | 461,061 | 639,639 |
| | 6,169,107 | 3,981,802 |

8. Trade and other payables (current)

| | 2023 Unaudited € | 2022 Audited € |
|---------------------------------------------|------------------------|----------------------|
| <i>Amounts falling due within one year:</i> | | |
| Trade payables | 1,270,907 | 1,071,692 |
| Payroll related taxes | 2,769,607 | 151,715 |
| Superannuation / retirement benefit | 68,368 | 44,278 |
| Other payables and accruals | 2,404,490 | 2,469,283 |
| Sales tax payable | 77,882 | 74,281 |
| Deferred income | 4,849,639 | 3,234,186 |
| R&D tax credit – deferred grant income | 129,318 | 99,220 |
| | 11,570,211 | 7,144,655 |

Included within payroll related taxes due at 31 December 2023 is €2,552,194 (2022: €2,476,858) relating to the Irish Revenue Commissioner Debt Warehousing scheme for the period May 2020 to December 2021. The Group is in discussions with the Irish Revenue Commissioners about a Phased Payment Arrangement. In accordance with the rules of the scheme, the Group had been accruing interest at a rate of 3% on the debt. On 5 February 2024, the Minister for Finance announced that the interest rate applicable to warehoused debt will be reduced to 0%. The interest accrued to 31 December 2023 totaling €75,336 will be reversed in the year ended 31 December 2024.

Notes to the Preliminary Final Report
for the year ended 31 December 2023

9. Trade and other payables (non-current)

| | 2023 Unaudited € | 2022 Audited € |
|-----------------------------|--------------------------------------|----------------------|
| Payroll related taxes | - | 2,476,858 |
| Other payables and accruals | 247,225 | 312,779 |
| | 247,225 | 2,789,637 |

10. Share capital

Authorised Share Capital

| | 2023 Unaudited | 2022 Audited |
|--------------------------------|---------------------------------|-----------------|
| Ordinary shares | | |
| No. of shares | 1,000,000,000 | 750,000,000 |
| Nominal value | €0.001 | €0.001 |
| "B" Ordinary shares | | |
| No. of shares | 420,000 | 420,000 |
| Nominal value | €0.01 | €0.01 |
| | € | € |
| Authorised Ordinary Shares | 1,000,000 | 750,000 |
| Authorised "B" Ordinary Shares | 4,200 | 4,200 |
| | 1,004,200 | 754,200 |

Notes to the Preliminary Final Report
for the year ended 31 December 2023

10. Share capital (continued)

| Issued share capital | No of ordinary shares | Par value of units | Share Capital | Share premium | Total |
|------------------------------------|-----------------------|--------------------|----------------|--------------------|--------------------|
| Balance at 1 January 2022 | 518,477,053 | €0.001 | 518,477 | 120,071,867 | 120,590,344 |
| Share issue – 13 Jan 2022 | 444,444 | €0.001 | 444 | - | 444 |
| Share issue – 11 Apr 2022 | 538,989 | €0.001 | 539 | - | 539 |
| Share issue – 4 May 2022 | 1,164,757 | €0.001 | 1,165 | - | 1,165 |
| Share issue – 20 Jun 2022 | 96,000 | €0.001 | 96 | - | 96 |
| Share issue – 7 Sept 2022 | 240,796 | €0.001 | 241 | - | 241 |
| Share issue – 3 Oct 2022 | 1,104,107 | €0.001 | 1,104 | - | 1,104 |
| Share issue – 2 Nov 2022 | 924,298 | €0.001 | 924 | - | 924 |
| Exercise of options – 9 Nov 2022 | 12,000,000 | €0.001 | 12,000 | 297,458 | 309,458 |
| Balance at 31 December 2022 | 534,990,444 | €0.001 | 534,990 | 120,369,325 | 120,904,315 |
| Share issue – 2 Mar 2023 | 552,466 | €0.001 | 552 | - | 552 |
| Share issue – 2 Aug 2023 | 111,111,111 | €0.001 | 111,111 | 12,057,300 | 12,168,411 |
| Share issue – 3 Aug 2023 | 457,500 | €0.001 | 458 | - | 458 |
| Share issue – 31 Aug 2023 | 15,612,474 | €0.001 | 15,613 | 1,655,759 | 1,671,372 |
| Share issue – 4 Sept 2023 | 3,154,377 | €0.001 | 3,154 | - | 3,154 |
| Share issue – 21 Sept 2023 | 1,316,667 | €0.001 | 1,317 | - | 1,317 |
| Share issue – 12 Nov 2023 | 106,666 | €0.001 | 107 | - | 107 |
| Share issue – 17 Nov 2023 | 2,097,189 | €0.001 | 2,097 | - | 2,097 |
| Share issue – 27 Nov 2023 | 2,083,333 | €0.001 | 2,083 | - | 2,083 |
| Balance at 31 December 2023 | 671,482,227 | €0.001 | 671,482 | 134,082,384 | 134,753,866 |

Notes to the Preliminary Final Report
for the year ended 31 December 2023

11. Reconciliation of net cash used in operating activities

| | 2023 | 2022 |
|---------------------------------------------------|--------------------|--------------|
| | Unaudited | Audited |
| | € | € |
| Loss for the year | (8,934,571) | (10,869,459) |
| <i>Non-cash items</i> | | |
| Depreciation | 309,554 | 460,013 |
| Loss on disposal of property, plant and equipment | - | 5,967 |
| Amortisation of software and development costs | 176,424 | 213,890 |
| Gain on modification of lease liabilities | - | (62,610) |
| R&D credit, net | (623,631) | (673,798) |
| Taxation | 49,735 | (55,221) |
| Net finance costs | 197,537 | 104,362 |
| Share based payment expense | 2,368,348 | 2,996,691 |
| Foreign exchange loss | 314,247 | 57,527 |
| Changes in assets and liabilities | | |
| Increase in inventories | (1,013,215) | (541,612) |
| Increase in trade and other receivables | (1,533,576) | (808,434) |
| (Increase)/decrease in contract assets | (190,871) | 69,431 |
| Increase/(decrease) in deferred income | 1,607,216 | (79,208) |
| Increase/(decrease) in trade and other payables | 181,389 | (228,148) |
| Cash used in operating activities | (7,091,414) | (9,410,609) |
| Finance charges paid | (127,455) | (104,932) |
| Interest received | 5,254 | 570 |
| Research and development tax credit received | - | 621,561 |
| Income tax paid | (50,173) | (16,671) |
| Net cash used in operating activities | (7,263,788) | (8,910,081) |



James Fitter
Chief Executive Officer

Date: 26 February 2024

Corporate Directory

**Registered office
and business address**

2nd Floor Avoca Court
Temple Road
Blackrock
Co. Dublin
Ireland

Independent auditor

KPMG
Chartered Accountants
1 Stokes Place
St. Stephen's Green
Dublin 2

Bankers

HSBC Bank Limited
Guildford and Weybridge Commercial Centre
Edgeborough Road
Guildford
Surrey GU12BJ
United Kingdom

Solicitors

A&L Goodbody
25-28 North Wall Quay
Dublin 1

Clayton Utz
Level 15
1 Bligh Street
Sydney
NSW 2000
Australia

Company secretary

Helena D'Arcy

Registry

Computershare Investor Services Pty Ltd
Level 4
60 Carrington Street
Sydney
NSW 2000
Australia

Company number

513842

ABRN:

610 611 768

ASX Code:

ASX: ONE

Company Website:

www.oneviewhealthcare.com